Harmony Biosciences (NASDAQ:HRMY – Get Free Report)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a note issued to investors on Wednesday, Benzinga reports. They presently have a $52.00 price objective on the stock. Needham & Company LLC’s price objective points to a potential upside of 32.52% from the stock’s current price.
HRMY has been the topic of several other reports. Citigroup began coverage on Harmony Biosciences in a research report on Friday, June 21st. They issued a “buy” rating and a $48.00 price objective on the stock. UBS Group initiated coverage on Harmony Biosciences in a research report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price target for the company. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Harmony Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $41.33.
Read Our Latest Report on HRMY
Harmony Biosciences Stock Down 1.9 %
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.24. The firm had revenue of $172.80 million during the quarter, compared to analyst estimates of $172.53 million. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The business’s revenue was up 28.8% on a year-over-year basis. During the same period last year, the business earned $0.56 earnings per share. On average, equities research analysts expect that Harmony Biosciences will post 2.19 earnings per share for the current year.
Hedge Funds Weigh In On Harmony Biosciences
Hedge funds and other institutional investors have recently modified their holdings of the business. TFO Wealth Partners LLC boosted its position in shares of Harmony Biosciences by 98,700.0% during the 4th quarter. TFO Wealth Partners LLC now owns 988 shares of the company’s stock worth $32,000 after purchasing an additional 987 shares during the period. nVerses Capital LLC purchased a new stake in shares of Harmony Biosciences during the second quarter worth approximately $36,000. Quarry LP purchased a new stake in Harmony Biosciences in the 2nd quarter valued at approximately $62,000. Headlands Technologies LLC grew its holdings in Harmony Biosciences by 1,608.1% during the second quarter. Headlands Technologies LLC now owns 2,545 shares of the company’s stock worth $77,000 after acquiring an additional 2,396 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Harmony Biosciences in the 2nd quarter valued at about $138,000. 86.23% of the stock is owned by hedge funds and other institutional investors.
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Featured Stories
- Five stocks we like better than Harmony Biosciences
- How to Most Effectively Use the MarketBeat Earnings Screener
- Analysts See 180% Upside for Rent the Runway: Should You Buy?
- P/E Ratio Calculation: How to Assess Stocks
- Ready for Growth? Barrick Gold Stock Could Be the Answer
- Health Care Stocks Explained: Why You Might Want to Invest
- Trade Like a Member of Congress With These 2 ETFs
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.